Word: statin
(lookup in dictionary)
(lookup stats)
Dates: during 2000-2009
Sort By: most recent first
(reverse)
...ages 50 and older and women ages 60 and older, who had high levels of C-reactive protein (CRP) but normal cholesterol levels and no history of heart disease. Half the participants were given rosuvastatin (Crestor), and half were given a placebo daily for just under two years. The statin group reduced their CRP levels by 37%; their LDL, or bad cholesterol, levels dropped 50% to about 55 mg/dL. Among the 8,901 statin-takers, 31 suffered a heart attack and 33 suffered a stroke. When compared with the placebo group, those figures translated to a 54% lower risk...
Although JUPITER (Justification for the Use of Statins in the Prevention: an Intervention Trial Evaluating Rosuvastatin) was designed to study inflammation, its findings also underscore the risk of high cholesterol. The study's statin group clearly benefited from reducing CRP, but they had also simultaneously lowered their LDL levels to nearly 50% below the government-prescribed target of 100 mg/dL. Experts say the JUPITER results may prompt serious rethinking of the current guidelines - an issue that health officials have already been debating in recent years. "I would not be surprised if, given these results, we determined that normal LDL should...
...over, but squeezes in risk information only once and just after the halfway mark. You won't see it on TV anymore - the drug maker pulled the ad in January after releasing results of a two-year trial that showed Vytorin was no better than a cheaper generic statin drug at preventing heart disease - but you can watch our dissection of it below...
...will take a while to catch on, but that should only further motivate this effort. When statistics consistently show that lifestyle and diet changes are more effective than any medicine, a patient should be happy with a prescription for a 30-minute run and cardamom roasted cauliflower with his statin any day. It’s a marriage worth fighting for.—Columnist Rebecca A. Cooper can be reached at cooper3@fas.harvard.edu...
...even there, Vytorin failed to show much effect. Vytorin is actually the combination of two drugs - one of the early statin medications, simvastatin (also known as Zocor), made by Merck, and ezetimibe, or Zetia, made by Schering-Plough. Ezetimibe is the first cholesterol-lowering medication that works by blocking absorption of cholesterol in the gut, rather than regulating the fat's production in the liver, like other statins do. ENHANCE compared the effect of Vytorin to simvastatin alone, and showed little difference between the two medications when it came to plaque size in the arteries. Simvastatin came off patent...